New CAR t therapy targets tough lymphoma
Disease control
Recruiting now
This early-phase trial is testing a new type of immune cell therapy called BAFFR-CAR T cells for people with relapsed or refractory B-cell Non-Hodgkin's lymphoma. The study aims to find a safe dose and check for side effects. About 36 adults whose cancer has not responded to prio…
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC